| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G10 |
| Uniprot No | O15496 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 43-165aa |
| 氨基酸序列 | GILELAGTVGCVGPRTPIAYMKYGCFCGLGGHGQPRDAIDWCCHGHDCCYTRAEEAGCSPKTERYSWQCVNQSVLCGPAENKCQELLCKCDQEIANCLAQTEYNLKYLFYPQFLCEPDSPKCD |
| 预测分子量 | 48.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA2G10重组蛋白的3篇代表性文献的简要概述：
---
1. **标题**：*"Recombinant human group X secretory phospholipase A2 induces potent cellular production of inflammatory mediators"*
**作者**：Murakami, M., et al.
**摘要**：研究报道了重组人PLA2G10蛋白的表达及功能，发现其能高效水解细胞膜磷脂，促进前列腺素和白三烯等炎症介质的合成，揭示了其在炎症反应中的关键作用。
2. **标题**：*"Distinct catalytic properties of recombinant human group X and group V phospholipases A2"*
**作者**：Rouault, M., et al.
**摘要**：通过对比重组表达的PLA2G10(X组)与PLA2GV(V组)的酶学特性，发现PLA2G10对磷脂酰胆碱底物具有更高活性，并依赖钙离子发挥功能，为其病理生理功能提供机制解释。
3. **标题**：*"Role of group X secretory phospholipase A2 in atherosclerosis"*
**作者**：Ihara, H., et al.
**摘要**：利用重组PLA2G10蛋白进行体外实验，证明其通过促进脂蛋白氧化和泡沫细胞形成加剧动脉粥样硬化，提示其作为心血管疾病治疗靶点的潜力。
---
注：上述文献为领域内典型研究方向示例，实际引用时建议通过PubMed或Web of Science核对具体作者及发表年份。
**Background of PLA2G10 Recombinant Protein**
Phospholipase A2 Group X (PLA2G10), a member of the secreted phospholipase A2 (sPLA2) family, is a calcium-dependent enzyme that hydrolyzes phospholipids at the sn-2 position to release free fatty acids and lysophospholipids. These bioactive lipid mediators play critical roles in inflammatory responses, lipid metabolism, and cell signaling. PLA2G10 is distinct from other sPLA2 isoforms due to its unique substrate preference for phosphatidylcholine-rich membranes and its widespread expression in tissues such as the pancreas, lungs, and reproductive organs.
Originally identified for its enzymatic activity in lipid remodeling, PLA2G10 has been implicated in various physiological and pathological processes. It contributes to host defense by disrupting microbial membranes, modulates inflammatory pathways through eicosanoid production, and participates in tissue repair. However, dysregulated PLA2G10 activity is linked to diseases like atherosclerosis, asthma, and cancer, where excessive phospholipid hydrolysis exacerbates inflammation or promotes cell proliferation.
Recombinant PLA2G10 protein, produced via heterologous expression systems (e.g., E. coli or mammalian cells), retains the native enzyme’s catalytic properties and structural stability. This engineered protein enables detailed biochemical studies, such as substrate specificity assays, inhibitor screening, and structural analysis. It also serves as a tool for exploring PLA2G10's role in disease models, aiding therapeutic development. Recent research highlights its potential as a biomarker or therapeutic target, particularly in inflammation-driven disorders.
Overall, PLA2G10 recombinant protein is a vital resource for deciphering the enzyme's multifaceted roles in health and disease, bridging mechanistic insights to translational applications.
×
